Indeed, multiple first-generation Hsp90 inhibitors showed promising results in HER2-positive breast cancer clinical trials, but their development was stalled due to significant adverse effects, in particular liver and ocular toxicities13. Here, ERBB2 is linked to breast carcinoma.